{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:09:37Z","timestamp":1790701777461,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpet.2026.104996","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:04:26Z","timestamp":1785510266000},"page":"104996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["US postmarketed drug removals: Analysis of discontinued and withdrawn drugs"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8007-4100","authenticated-orcid":false,"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9512-4870","authenticated-orcid":false,"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jpet.2026.104996_bib1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/pds.2155","article-title":"Market withdrawal of new molecular entities approved in the United States from 1980 to 2009","volume":"20","author":"Qureshi","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"D1","key":"10.1016\/j.jpet.2026.104996_bib4","doi-asserted-by":"crossref","first-page":"D1307","DOI":"10.1093\/nar\/gkab918","article-title":"NCATS Inxight Drugs: a comprehensive and curated portal for translational research","volume":"50","author":"Siramshetty","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jpet.2026.104996_bib5","author":"Gohlke"},{"issue":"3","key":"10.1016\/j.jpet.2026.104996_bib6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jlme.12079","article-title":"Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009","volume":"41","author":"Outterson","year":"2013","journal-title":"J Law Med Ethics"},{"issue":"18","key":"10.1016\/j.jpet.2026.104996_bib7","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.3390\/ijms20184513","article-title":"Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018","volume":"20","author":"Li","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jpet.2026.104996_bib8","first-page":"196","article-title":"Drug-associated cardiovascular risks: a retrospective evaluation of withdrawn drugs","volume":"6","author":"Kocadal","year":"2018","journal-title":"North Clin Istanb"},{"key":"10.1016\/j.jpet.2026.104996_bib9","series-title":"Federal Food, Drug, and Cosmetic Act. eCFR system, National Archives","article-title":"U.S. Government. \u00a7216.24 Drug products withdrawn or removed from the market for reasons of safety or effectiveness","year":"2018"},{"issue":"4","key":"10.1016\/j.jpet.2026.104996_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2026.104317","article-title":"FDA black box warnings: characteristics of drug classes and adverse effects","volume":"393","author":"Bindel","year":"2026","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.jpet.2026.104996_bib12","doi-asserted-by":"crossref","first-page":"15515","DOI":"10.1007\/s00210-025-04178-9","article-title":"New drugs and their performance 10 years after approval: a systematic analysis","volume":"398","author":"Manfouo","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104996_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00210-025-04412-4","article-title":"Comparison of drug approvals of the FDA and EMA between 2013 and 2023","volume":"399","author":"Lau","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104996_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00210-025-04370-x","article-title":"The change in the pharmacological significance of dihydralazine (Germany) and hydralazine (USA)","volume":"399","author":"Mech","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104996_bib15","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1007\/s00210-023-02877-9","article-title":"Presentation of the obsolete drug reserpine in three German-language pharmacology textbooks","volume":"397","author":"Misera","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"10.1016\/j.jpet.2026.104996_bib16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00210-023-02475-9","article-title":"Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany","volume":"396","author":"Obst","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104996_bib17","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00210-024-03377-0","article-title":"Updated analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany","volume":"398","author":"Obst","year":"2025","journal-title":"Naunyn Schmiedeberg Arch Pharmacol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104996_bib18","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1007\/s00210-024-03615-5","article-title":"The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis","volume":"398","author":"Schr\u00f6der","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpet.2026.104996_bib19","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1007\/s00210-026-05201-3","article-title":"Critical analysis of the prescription and evaluation of monoclonal antibodies approved in Germany for the outpatient setting from 2010\u20142021","volume":"399","author":"T\u00f6dter","year":"2026","journal-title":"Naunyn Schmiedeberg Arch Pharmacol"},{"key":"10.1016\/j.jpet.2026.104996_bib24","article-title":"Last US manufacturer of drug used in executions stops production","volume":"342","author":"Dyer","year":"2011","journal-title":"BMJ"},{"issue":"D1","key":"10.1016\/j.jpet.2026.104996_bib27","doi-asserted-by":"crossref","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","article-title":"The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods","volume":"52","author":"Zdrazil","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jpet.2026.104996_bib28","series-title":"Danthron laxatives are banned by FDA","year":"1987"},{"issue":"9","key":"10.1016\/j.jpet.2026.104996_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5694\/j.1326-5377.1984.tb108224.x","article-title":"The innocent bystander. Doxylamine\/dicyclomine\/pyridoxine and congenital limb defects","volume":"140","author":"McCredie","year":"1984","journal-title":"Med J Aust"},{"key":"10.1016\/j.jpet.2026.104996_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105841","article-title":"Pentylenetetrazole: a review","volume":"180","author":"Monteiro","year":"2024","journal-title":"Neurochem Int"},{"key":"10.1016\/j.jpet.2026.104996_bib41","series-title":"Wikipedia, the free Encyclopedia","article-title":"Gallamine triethiodide","year":"2026"},{"issue":"1","key":"10.1016\/j.jpet.2026.104996_bib42","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1186\/s12889-025-24005-3","article-title":"A study of demographic and clinical characteristics of consumers of non-steroidal anti-inflammatory drugs: a large population-based study utilizing enrollment phase data from the tabari cohort","volume":"25","author":"Hessami","year":"2025","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.jpet.2026.104996_bib43","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.amjms.2016.08.028","article-title":"Overuse and misperceptions of nonsteroidal anti-inflammatory drugs in the United States","volume":"352","author":"Cryer","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jpet.2026.104996_bib45","series-title":"UF Health","article-title":"UF study: FDA label change requirement helped reduced antibiotic misuse","author":"Baltich","year":"2021"},{"issue":"5","key":"10.1016\/j.jpet.2026.104996_bib46","first-page":"49","article-title":"Awareness of the use of non-steroidal anti-inflammatory drugs: a cross-sectional study","volume":"5","author":"Chkhikvadze","year":"2025","journal-title":"Med Int (Lond)"},{"key":"10.1016\/j.jpet.2026.104996_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1362632","article-title":"Consumer awareness and knowledge regarding use of non-steroidal anti-inflammatory drugs (NSAIDs) in a metropolitan area","volume":"15","author":"Montuori","year":"2024","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.jpet.2026.104996_bib48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2009.07.007","article-title":"Precaution, cyclooxygenase inhibition, and cardiovascular risk","volume":"30","author":"Ritter","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"7471","key":"10.1016\/j.jpet.2026.104996_bib49","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/bmj.329.7471.867","article-title":"Lessons from the withdrawal of rofecoxib","volume":"329","author":"Dieppe","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jpet.2026.104996_bib50","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-9343(70)80129-2","article-title":"The role of the liver in drug metabolism","volume":"49","author":"Remmer","year":"1970","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.jpet.2026.104996_bib51","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.18203\/2319-2003.ijbcp20184211","article-title":"The role of liver in metabolism: an updated review with physiological emphasis","volume":"7","author":"Alamri","year":"2018","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.jpet.2026.104996_bib52","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1753-6561-3-S2-S2","article-title":"Systems biology for identifying liver toxicity pathways","volume":"3","author":"Li","year":"2009","journal-title":"BMC Proc"},{"issue":"12","key":"10.1016\/j.jpet.2026.104996_bib53","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.3390\/ijms26125825","article-title":"Liver metabolism at the crossroads: the reciprocal control of nutrient-sensing nuclear receptors and autophagy","volume":"26","author":"Kim","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jpet.2026.104996_bib54","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/med.21476","article-title":"Comprehensive review of cardiovascular toxicity of drugs and related agents","volume":"38","author":"Mlad\u011bnka","year":"2018","journal-title":"Med Res Rev"},{"issue":"2","key":"10.1016\/j.jpet.2026.104996_bib55","first-page":"114","article-title":"Hematologic side effects of drugs","volume":"19","author":"Lubran","year":"1989","journal-title":"Ann Clin Lab Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104996_bib56","article-title":"Drug-induced hematologic syndromes","volume":"2009","author":"Mintzer","year":"2009","journal-title":"Adv Hematol"},{"key":"10.1016\/j.jpet.2026.104996_bib57","series-title":"Wikipedia, the free Encyclopedia","article-title":"Pyridoxine\/doxylamine","year":"2025"},{"key":"10.1016\/j.jpet.2026.104996_bib58","series-title":"History of EMA","year":"2026"},{"key":"10.1016\/j.jpet.2026.104996_bib59","article-title":"National competent authorities (human)","year":"2026","journal-title":"Partners and networks"},{"key":"10.1016\/j.jpet.2026.104996_bib60","series-title":"Authorisation of medicines","year":"2026"},{"key":"10.1016\/j.jpet.2026.104996_bib61","article-title":"Medicines data table. Download medicine data","year":"2026","journal-title":"Medicines"},{"issue":"1","key":"10.1016\/j.jpet.2026.104996_bib63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bcp.14130","article-title":"Food and Drug Administration vs European Medicines Agency: review times and clinical evidence on novel drugs at the time of approval","volume":"86","author":"Joppi","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104996_bib64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s43441-023-00574-6","article-title":"Comparison between European Medicines Agency and US Food and Drug Administration in granting accelerated marketing authorizations for COVID-19 medicines and their utilized regulations","volume":"58","author":"Ghadanian","year":"2024","journal-title":"Ther Innov Regul Sci"},{"issue":"5","key":"10.1016\/j.jpet.2026.104996_bib65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacbts.2016.06.003","article-title":"Drugs and devices: comparison of European and U.S. approval processes","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jpet.2026.104996_bib66","article-title":"Transatlantic regulatory divergence in pharmaceuticals: exploring economic and cultural explanations","author":"Wells","year":"2024","journal-title":"Universit\u00e4t Hamburg"},{"issue":"6","key":"10.1016\/j.jpet.2026.104996_bib67","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/03007995.2025.2537298","article-title":"Cross-cultural treatment preferences: a call for diversity in drug development","volume":"41","author":"Dijkgraaf","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpet.2026.104996_bib68","series-title":"Basic Knowledge of Pharmacology","author":"Seifert","year":"2019"},{"key":"10.1016\/j.jpet.2026.104996_bib69","series-title":"PubMed. Search","year":"2026"},{"issue":"1","key":"10.1016\/j.jpet.2026.104996_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1124\/jpet.121.000852","article-title":"Thiabendazole inhibits glioblastoma cell proliferation and invasion targeting mini-chromosome maintenance protein 2","volume":"380","author":"Hu","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104996_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102548","article-title":"Exploring the therapeutic role of thiabendazole in lung adenocarcinoma via network pharmacology and single-cell analysis","volume":"62","author":"Qi","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jpet.2026.104996_bib72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejogrb.2024.02.034","article-title":"Research progress of dydrogesterone in the treatment of endometriosis","volume":"296","author":"Tang","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jpet.2026.104996_bib73","series-title":"National Library of Medicine (NIH)","year":"2026"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:44:43Z","timestamp":1790700283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022356526011961"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104996","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"US postmarketed drug removals: Analysis of discontinued and withdrawn drugs","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104996"}}